Traditional immunosuppressive therapies have targeted the T-cell compartment of the reconstituting immune system, but clinical responses to these agents have been limited, with failure-free survival after second line therapy being only 20%. 6 The inability to achieve a robust B-cell tolerance is a hallmark of active cGvHD and approaches that incorporate B-cell-directed therapies have been studied to meet this clinical need.
Rituximab, a monoclonal anti-CD20 ab, has resulted in improvement of symptoms in patients with steroid-refractory cGvHD, especially those with sclerodermatous or lichenoid cutaneous manifestations, with response rates ranging from 43-83%. 7, 8 However, our understanding of disease response to B-cell targeted treatment is still evolving. Given the typical extent of tissue sclerosis in cGvHD, it can be difficult to differentiate persistent active cGvHD from residual tissue damage without active inflammation based upon clinical criteria alone. This report describes how immunophenotypic evidence of normal B-cell recovery following B-cell depleting therapy with rituximab may be a clinical tool to evaluate disease response that may inform regarding clinical management.
A nutritional support with total parenteral nutrition. She was gradually weaned off immunosuppressive medication over 10 months but remained on prednisone 10 mg daily.
The patient first developed symptoms of severe extensive cGvHD in June 2010. Initial manifestations included extensive lichenoid changes in the mouth with superficial ulcerations as well as vaginal GvHD manifestions of dyspareunia and dryness. She was initially managed with prednisone and mycophenolate mofetil (therapies for cGvHD depicted graphically in Figure 1 ). Over the next year, she developed worsening sclerotic changes to the skin and fascia of her thighs that limited her mobility, as well as ocular xerostomia. She was started on sirolimus, but with worsening of overall skin/fascia GvHD. A month later, she was started on a 12-month course of photopheresis, with modest improvement in her symptoms. Sirolimus was stopped and a few months later tacrolimus was started. Although these therapies allowed for some taper in her corticosteroid dose, she remained on high-dose prednisone (430 mg daily). In February 2013, rituximab weekly × 4 doses was administered. Over the next year, the patient experienced slow, steady improvement in symptoms, affording cessation of mycophenolate mofetil and tacrolimus. Tapering of prednisone was accomplished over the subsequent year, with gradual dose reduction from 40 mg daily to 10 mg daily, but the patient continued to experience musculoskeletal pain. Thus, in December 2014, two infusion of rituximab were administered, though question remained whether further rituximab therapy would be beneficial.
Absolute CD19+ lymphocyte counts and quantitative serum IgM levels were determined throughout the course of post-transplant therapy. We found robust B-cell recovery with supernormal B-cell numbers following the initial rituximab administration (Figure 1) . The rapid recovery of B cells in the blood following treatment with rituximab is consistent with normal physiological regulation of BAFF during B-cell ontogeny. 2 Notably, absolute T-cell counts remained stable throughout therapy. Peripheral blood flow-cytometric analysis 9 months after the first dose of a potential second cycle of rituximab demonstrated early signs of naive B-cell recovery typical of patients with stable/improved response to rituximab (absolute CD19, 178/μL; large composition of transitional B cells (CD27-CD38+ IgD+; Figure 2) . 9 Given the previous reports showing a significant association between robust B-cell recovery and response to rituximab, 10 this patient's symptoms of joint pain and stiffness were potentially not related to active disease, but rather related to chronic scarring and steroid-induced myopathy. Thus, instead of pursuing further immunotherapies, the patient entered an intensive physical therapy-based exercise regimen and fully tapered off all immunosuppression with significant improvement of her symptoms.
It has previously been reported that cGvHD patients who respond to rituximab therapy have more rapid recovery of B cells in the blood as compared with non-responders. 9 When rituximab was administered early after HCT as potential cGvHD prophylaxis, 11 early recovery of B cells and decreased BAFF/B ratios were associated with aversion of cGvHD. As mature B cells have higher levels of BAFF receptors, B cells sequester BAFF and prevent further promotion of autoreactive B-cell clone survival. In this case report, we demonstrate how measurement of the kinetics of B-cell recovery following rituximab therapy might be used in real-time clinical decision-making. The patient had persisting musculoskeletal pain and joint stiffness 25 months after receiving 4 doses of rituximab. On the basis of clinical criteria and the presence of sclerodermatous changes in the skin and vaginal GvHD, it was difficult to know whether cGvHD remained active. Review of B-cell recovery kinetics showed an increase in serum IgM preceding a robust recovery of CD19+ B cells, consistent with the recovery seen patients with stable/improved symptoms following rituximab. 9 Flow cytometry identified the presence of CD27 negative naive and transitional B cells (CD27 − CD38+ IgD+ and CD27 − CD38Hi IgD+) seen with in rituximab responsive patients. By contrast, patients whose cGvHD is unresponsive to rituximab experience persistent profound B lymphopenia with a predominance of CD27+ cells. 9 Utilizing evolving knowledge regarding B-cell pathophysiology in cGvHD, we propose further examination of immunophenotypic expression patterns on peripheral blood B-cell subsets as potential tools in for monitoring responses to B-cell depleting therapy.
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